人参固本口服液抗肾纤维化主要化学成分及机制识别
研究采用UPLC-QTOF-MS/MS表征人参固本口服液化学成分,并建立小鼠单侧输尿管梗阻模型评价其抗肾纤维化作用。共鉴定或初步表征201种成分,网络分析与实验验证表明该药可能通过调控Tgfβ1/Smad2/3、Wnt4/β-Catenin和NGFR/NF-κB通路减轻肾纤维化。
要点
- 人参固本口服液可改善UUO小鼠血清BUN和Scr水平及肾脏病理结构。
- 该药含201种化学成分,其中三萜类49种、酚类46种,26种为关键活性成分。
- 机制涉及抑制Tgfβ1/Smad2/3、Wnt4/β-Catenin和NGFR/NF-κB通路活化。
核心结论
- 人参固本口服液首次被表征出201种化学成分,其中26种关键活性成分可能通过Tgfβ1/Smad2/3、Wnt4/β-catenin和NGFR/NF-κB通路缓解肾纤维化。
研究设计与样本
- 采用UPLC-QTOF-MS/MS描述人参固本口服液化学轮廓,并建立小鼠单侧输尿管梗阻模型评价其对肾纤维化的作用。
- 通过生化指标、HE和Masson染色评估药效,利用RNA测序和「成分-靶点-通路」多维网络挖掘机制,并用qRT-PCR和WB验证关键靶点。
主要发现
- 共鉴定或初步表征201种成分,其中15种经标准品确认,三萜类数量最多为49种,酚类次之为46种。
- RSGB改善UUO小鼠血清BUN和Scr水平,并使肾组织病理结构正常化。
- RNA测序显示RSGB调控226个差异基因,涉及肾脏发育。
- 「成分-靶点-通路」网络提示26种关键活性成分可能通过88个对应靶点主要调控炎症免疫系统。
- qRT-PCR和WB结果显示RSGB抑制Tgfβ1/Smad2/3通路、Wnt4/β-Catenin通路和NGFR/NF-κB通路的激活。
临床怎么用
- 对于慢性肾炎相关肾纤维化患者,人参固本口服液可能通过多成分、多靶点调控炎症免疫及纤维化通路发挥益处。
- 临床决策时可关注该药对BUN、Scr及肾脏病理结构的改善作用,但需结合患者具体证候与病情。
局限性
- 研究基于小鼠UUO模型,尚需临床研究验证人参固本口服液对肾纤维化患者的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal fibrosis is the late stage of many chronic kidney diseases (CKD). Clinically, there is almost no effective treatment for renal fibrosis except dialysis. Renshen Guben oral liquid (RSGB) is a Chinese patent medicine approved by National Medical Products Administration (NMPA), which is suitable for clinical patients with chronic nephritis. Currently, the chemical constituents of RSGB remains unclear, and its efficacy and mechanism on renal fibrosis have not been reported. METHODS: In our research, ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS/MS) was employed to describe the chemical profile of RSGB, unilateral ureteral obstruction (UUO) model in mice was established to evaluate the beneficial effect of RSGB on renal fibrosis by biochemical indexes, HE and Masson staining. RNA sequencing and "constituents-targets-pathways" multi-dimensional network was established to mine the mechanisms of RSGB. Key targets were verified by quantitative real-time PCR (qRT-PCR) and western bolt (WB). RESULTS: A total of 201 constituents were identified or tentatively characterized, 15 of which were confirmed with standards. The number of triterpenes was the highest with 49, followed by phenols with 46. RSGB ameliorated the blood urea nitrogen (BUN) and serum creatinine (Scr) levels in serum, normalizing pathological structure of kidney tissue. RNA sequencing revealed that RSGB regulates 226 differential genes, which were involved in kidney development. According to the "constituents-targets-pathways" network, 26 key active constituents may mainly regulate the inflammatory immune system through 88 corresponding targets. qRT-PCR and WB results showed that RSGB inhibited the activation of the Tgfβ1/Smad2/3 pathway, Wnt4/β-Catenin pathway and NGFR/NF-κB pathway. CONCLUSIONS: Overall, our study, for the first time, characterized 201 chemical constituents in RSGB, and 26 of them were screened out to alleviates renal fibrosis mainly through Tgfβ1/Smad2/3 pathway, Wnt4/β-catenin pathway and NGFR/NF-κB pathway, which may provide a new research strategy for research on the mechanism of traditional Chinese Medicine.
引用
- Zhang J, Peng J, Zhang T, et al. Identification of the Main Chemical constituents and mechanism of Renshen Guben oral liquid against Renal Fibrosis. Chin Med. 2023. PMID: 37198665. doi:10.1186/s13020-023-00762-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。